Prophylactic Probiotics to Prevent Death or Sepsis in Preterm Infants in Colombia. A randomized, double-blind, multicenter trial.
Neonatal infections currently cause about 1.6 million deaths annually in developing countries. Preterm infants are especially vulnerable to infections because of their immature immune responses and their exposure to the hospital milieu, which promotes gastrointestinal colonization with Gram-negative...
- Autores:
-
Lozano Leòn, Juan Manuel
- Tipo de recurso:
- Investigation report
- Fecha de publicación:
- 2011
- Institución:
- Ministerio de Ciencia, Tecnología e Innovación
- Repositorio:
- Repositorio Minciencias
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.minciencias.gov.co:20.500.14143/40267
- Acceso en línea:
- https://repositorio.minciencias.gov.co/handle/20.500.14143/40267
- Palabra clave:
- Bajo peso al nacer
Mortalidad Neonatal
Neonato pretérmino
Probióticos
Sepsis neonatal
- Rights
- openAccess
- License
- Derechos Reservados - Pontificia Universidad Javeriana, 2021
| Summary: | Neonatal infections currently cause about 1.6 million deaths annually in developing countries. Preterm infants are especially vulnerable to infections because of their immature immune responses and their exposure to the hospital milieu, which promotes gastrointestinal colonization with Gram-negative pathogens. Multiple studies have shown that the colonization of the bowel with probiotics (nonpathogenic anaerobic bacteria) competitively inhibit the attachment of Gram-negative pathogens decreasing their likelihood for bacterial translocation and the development of life threatening infections. This potential high-impact, low-cost intervention may significantly improve the survival and morbidity of preterm infants around the world. We propose to use the Colombian Neonatal Research Network (CNRN), a well-established and successful clinical research network, to test this hypothesis. |
|---|